AbbVie to Acquire Allergan for $63B

 AbbVie to Acquire Allergan for $63B

AbbVie to Acquire Allergan for its Portfolio in Medical Aesthetics and Ophthalmology for $63B


  • AbbVie to acquire Allergan in cash & stock transaction making the total deal value $63B, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. The transaction represents a 45% premium to the closing price of shares of Allergan on June 24, 2019
  • Allergan shareholders to receive 0.8660 shares in AbbVie and $120.30 in cash for each share in Allergan for a total consideration of $188.24/share of Allergan. The focus of the acquisition is to expand AbbVie’s revenue base with addition of Allergan’s medical aesthetics and ophthalmology portfolio
  • Post-acquisition AbbVie’s shareholder will own ~83% of AbbVie and Allergan’s shareholders will own ~17% of AbbVie on a fully diluted basis. The transaction is expected to close in H1’20

Click here to read full press release/ article | Ref: AbbVie | Image: Allergan

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post